Peptides / Sexual health and hormones

Synthetic analog · 9 amino acids · 1,069.2 Da

Desmopressin

ApprovedBanned in sport

Desmopressin (DDAVP) is a synthetic vasopressin analog approved in the US for diabetes insipidus and bedwetting, also approved in EU countries, and banned in sport. Studies in people tested it mostly on bleeding and clotting, bladder control and bedwetting, and tracked side effects. PepBank shows 622 results on desmopressin from 115 studies in people, and 73 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as DDAVP

9 amino acids, from first to lastXYFQNCPRG

Evidence level: Large trials in people622 of 695 results come from studies in people, including randomized trials.

Results in people

622

89% of 695 results

Results in animals

10% of 695 results

Results in lab cells

under 1% of 695 results

From computer models

0% of 695 results

Overview

Desmopressin at a glance

What it is	Synthetic analog, 9 amino acids
Approval	Approved in the US and EU (Ddavp)
In sport	Banned in sport (WADA S5)
Studies	138 studies with results. 135 of them gave desmopressin, with 695 results. 622 in people72 in animals1 in lab cells
Best study in people	Randomized controlled trial with 385 people (2013)
Clinical trials	102 registered: 14 active or planned, 18 with posted results
Community use	Initial oral desmopressin acetate tablet treatment for central diabetes insipidus in adults and children aged 4 years or older

The science

What is desmopressin?

Desmopressin is a deamino-D-arginine analog of vasopressin.

Amino acids in one chain

The history of desmopressin

1973
The oldest paper on desmopressin in PepBank is from 1973.
2007May
A registered trial of desmopressin started (NCT00477490).

Desmopressin structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 9 amino acidsFrom the first amino acid to the last

X1YFQN5CP+RG

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Desmopressin is a synthetic analog of 9 amino acids, with a ring, 1 disulfide bond, 2 changed amino acids.

Formula

C₄₆H₆₄N₁₄O₁₂S₂

Molecular weight

1,069.2 g/mol

CAS number

16679-58-6

Target

Vasopressin V2 receptor (gene AVPR2): agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 5311065, ChEMBL CHEMBL1429, UNII ENR1LLB0FP, DrugBank DB00035

Full sequence, SMILES and InChIKey

InChIKey
NFLWUMRGJYTJIN-PNIOQBSNSA-N

SMILES
C1C[C@H](N(C1)C(=O)[C@@H]2CSSCCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What desmopressin studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people622 of 695 results come from studies in people, including randomized trials.

Blood and clotting

234 results · 224 in people · 10 animal

In elective cardiac surgery, desmopressin and placebo produced similar blood loss. The New England journal of medicine, 1989

Top results

In elective cardiac surgery, desmopressin and placebo produced similar blood loss. (The New England journal of medicine, 1989)
In cardiac surgery patients with abnormal clot tests, clot ratios were higher with desmopressin than with placebo. (Lancet, 1999)
In children after cardiac surgery, desmopressin did not reduce blood loss compared with placebo. (The Journal of thoracic and cardiovascular surgery, 1993)

Kidneys and bladder

239 results · 221 in people · 18 animal

In Japanese nocturia patients, desmopressin 25 μg reduced night-time urination more than placebo. BJU international, 2013

Top results

In Japanese nocturia patients, desmopressin 25 μg reduced night-time urination more than placebo. (BJU international, 2013)
In patients with severe bedwetting, desmopressin and alarm had similar rates of at least 50% fewer wet nights. (Journal of pediatric urology, 2011)
In children with enuresis and voiding dysfunction, adding desmopressin to oxybutynin showed 71% success versus 54% with oxybutynin alone. (European urology, 1997)

Hormones

14 results · 14 in people

After desmopressin, 11/18 subjects responded based on ACTH and cortisol output. Clinical endocrinology, 1999

Top results

After desmopressin, 11/18 subjects responded based on ACTH and cortisol output. (Clinical endocrinology, 1999)
In children with diabetes insipidus, DDAVP did not change cortisol levels during sleep. (The Journal of pediatrics, 1978)
In chronic schizophrenia, four neurochemical concentrations and the growth hormone response to clonidine did not change during DDAVP therapy. (Neuropsychobiology, 1989)

Heart and blood vessels

14 results · 13 in people · 1 animal

In patients with POTS, desmopressin did not change standing blood pressure compared with placebo. Heart rhythm, 2012

Top results

In patients with POTS, desmopressin did not change standing blood pressure compared with placebo. (Heart rhythm, 2012)
In patients with POTS, desmopressin lowered standing heart rate compared with placebo. (Heart rhythm, 2012)
In aspirin-pretreated coronary bypass patients, thrombotic complications did not differ between desmopressin and placebo. (The Journal of thoracic and cardiovascular surgery, 1992)

Sleep

13 results · 13 in people

In adults with nocturia, higher desmopressin doses were linked to longer first sleep periods than lower doses. Neurourology and urodynamics, 2012

Top results

In adults with nocturia, higher desmopressin doses were linked to longer first sleep periods than lower doses. (Neurourology and urodynamics, 2012)
In men with nocturia, desmopressin improved sleep quality compared with placebo. (The Journal of urology, 2013)
In women with nocturia, desmopressin delayed first urination by 49 minutes compared with placebo. (The Journal of urology, 2013)

Pain

9 results · 9 in people

In patients with renal colic, pain at 10 minutes did not differ significantly between desmopressin and diclofenac. BJU international, 2001

Top results

In patients with renal colic, pain at 10 minutes did not differ significantly between desmopressin and diclofenac. (BJU international, 2001)
In spinal fusion patients, analgesic treatment duration did not differ significantly with desmopressin versus placebo before adjustment. (Annals of internal medicine, 1987)
In renal colic, pain at 20 minutes was 5.0 with desmopressin and 3.7 with diclofenac; the authors call all treatments equally effective then. (BJU international, 2001)

Desmopressin has 1,099 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 138 desmopressin studies by area Open the Scientific page

Key desmopressin studies

Studies in people come first, then studies in animals and in the lab.

People
Efficacy and safety of low dose desmopressin orally disintegrating tablet in men with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study
Weiss et al. 2013 · The Journal of urology · 385 people · cited by 61
11 results
People
Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study
Sand et al. 2013 · The Journal of urology · 261 people · cited by 57
8 results
People
Desmopressin acetate in percutaneous ultrasound-guided kidney biopsy: a randomized controlled trial
Manno et al. 2011 · American journal of kidney diseases : the official journal of the National Kidney Foundation · 162 people · cited by 76
4 results
People
Gender difference in efficacy and dose response in Japanese patients with nocturia treated with four different doses of desmopressin orally disintegrating tablet in a randomized, placebo-controlled trial
Yamaguchi et al. 2013 · BJU international · 116 people · cited by 39
13 results
People
Low-dose Desmopressin and Tolterodine Combination Therapy for Treating Nocturia in Women with Overactive Bladder: A Double-blind, Randomized, Controlled Study
Rovner et al. 2018 · Lower urinary tract symptoms · 106 people · cited by 22
8 results

All 138 Desmopressin studies

Desmopressin clinical trials

ClinicalTrials.gov lists 102 trials of desmopressin. 14 are active or planned, and 18 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Phase 3completed799 people

An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving ("Melt") Formulation of Desmopressin for the Treatment of Nocturia in Adults

Phase 3completed554 people

Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients

Phase 3completed395 people

All 27 Desmopressin trials

Status and safety

Is desmopressin approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S5.

Yes. Approved in the US and EU (Ddavp). The FDA label for Ddavp says: “Antidiuretic replacement in central diabetes insipidus, temporary polyuria and polydipsia after head trauma or pituitary-region surgery, and primary nocturnal enuresis” Banned in sport (WADA S5).

Laws and labels change, so check the regulator for the current status.

Desmopressin side effects and safety

PepBank has 86 safety results from studies of desmopressin. 81 of them come from studies in people.

Safety results from studies (86)

In men with nocturia, adverse events affected similar numbers: 17% with desmopressin and 25% with placebo. (BJU international, 2002)
In women with overactive bladder, safety was similar with added desmopressin and tolterodine alone. (Lower urinary tract symptoms, 2018)
In elective aortic operation patients, major clot-related complications were similar with DDAVP and placebo. (Journal of vascular surgery, 1995)
In aspirin-pretreated coronary bypass patients, thrombotic complications did not differ between desmopressin and placebo. (The Journal of thoracic and cardiovascular surgery, 1992)
In brain haemorrhage patients, serious adverse events occurred in 44% with desmopressin versus 48% with placebo. (The Lancet. Neurology, 2023)
In elective CABG, neither DDAVP nor placebo patients showed hypercoagulability. (Journal of cardiothoracic anesthesia, 1989)
In men with nocturia, low sodium occurred in 2 subjects on desmopressin 50 μg versus 9 on 75 μg. (The Journal of urology, 2013)
In severe leptospirosis with lung involvement, eight desmopressin recipients died versus three controls. Mortality did not differ significantly. (Clinical microbiology and infection, 2010)
In breast cancer patients receiving desmopressin around surgery, two of 20 had reversible adverse events. (SpringerPlus, 2015)
No children withdrew from the trial, including the desmopressin-alone arm. (Medicine, 1998)
In children and adolescents receiving desmopressin, no serious or severe adverse events were reported. (International journal of clinical practice, 2007)
In Japanese nocturia patients, no serious adverse events occurred with desmopressin. (BJU international, 2013)
In hepatectomy patients, the study reported no changes in plasma electrolyte levels with desmopressin or saline. (Canadian journal of anaesthesia = Journal canadien d'anesthesie, 2003)
In elderly patients with prostate enlargement, desmopressin gradually lowered blood sodium compared with before treatment. (The Journal of urology, 2011)
In children with relapsed bedwetting, continued desmopressin treatment was well tolerated and caused no adverse reactions. (The Journal of urology, 1991)
After knee replacement, neither group, including desmopressin, showed clinical signs of deep vein thrombosis. (Transfusion, 2001)
After cardiopulmonary bypass, no drug-related side effects occurred with two DDAVP doses. (Circulation, 1994)
In patients with multiple sclerosis, desmopressin side effects were well tolerated. (Acta neurologica Scandinavica, 1996)
In patients with nocturia, side effects during DDAVP treatment were minimal. (British journal of urology, 1982)
Patients with multiple sclerosis did not report increased night-time urination during the desmopressin trial. (Journal of neurology, neurosurgery, and psychiatry, 1998)
Four elderly men experienced side effects on desmopressin. (BJU international, 1999)
In elderly subjects with nocturia, desmopressin was well tolerated and no serious adverse events occurred. (BJU international, 1999)
In patients with multiple sclerosis, 4 of 17 left the desmopressin study after low blood sodium developed. (Archives of neurology, 1996)
No adverse effects were noted during DDAVP treatment of children with bedwetting. (Archives of disease in childhood, 1982)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
25 μg once daily	Human	human	oral	3 months	Randomized trial in people · n = 261	Sand 2013
0.3 μg/kg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 162	Manno 2011
50 μg	Human	human	oral	3 months	Randomized trial in people	Weiss 2013
75 μg	Human	human	oral	3 months	Randomized trial in people	Weiss 2013
300 micro g	Human	human	nasal spray	2 months	Randomized trial in people	Kadir 2002
25 μg	Human	human	oral	28 days	Randomized trial in people	Yamaguchi 2013
50 μg	Human	human	oral	28 days	Randomized trial in people	Yamaguchi 2013
100 μg	Human	human	oral	28 days	Randomized trial in people	Yamaguchi 2013
0.2 mg	Human	human	oral	2 weeks	Randomized trial in people	Hashim 2009
50 μg	Human	human	oral	12 weeks	Randomized trial in people	Yamaguchi 2020
25 μg	Human	human	oral	12 weeks	Randomized trial in people	Yamaguchi 2020
120 mcg/day, then 60 mcg/day for 15 days and 60 mcg every second evening for 15 days	Human	human	sublingual	3 months before withdrawal	Randomized trial in people	Ferrara 2014
25 µg once daily	Human	human	oral	3 months	Randomized trial in people	Rovner 2018
10, 25, 50, or 100 µg	Human	human	oral	4 weeks	Randomized trial in people · n = 757	Weiss 2012
50 and 75 μg	Human	human	oral	3 months	Randomized trial in people · n = 385	Weiss 2013
0.2-0.4 mg daily	Human	human	oral	6 months	Randomized trial in people · n = 251	Evans 2011
120/240 microg MELT; 0.2/0.4 mg tablets	Human	human	sublingual MELT; oral tablet	3 weeks per formulation	Randomized trial in people · n = 221	Lottmann 2007
melt 120/240 μg or tablet 0.2/0.4 mg	Human	human	oral	3 weeks per period	Randomized trial in people · n = 221	Juul 2013
120 µg	Human	human	oral melt	2 weeks	Randomized trial in people · n = 206	Montaldo 2012
0.2-0.6 mg	Human	human	oral	2 weeks	Randomized trial in people · n = 193	Schulman 2001
0.1, 0.2 or 0.4 mg	Human	human	oral	3 weeks	Randomized trial in people · n = 151	Mattiasson 2002
0.3 microgram per kilogram	Human	human	intravenous	Not reported	Randomized trial in people · n = 150	Hackmann 1989
0.1 mg, 0.2 mg, or 0.4 mg	Human	human	oral	3 weeks	Randomized trial in people · n = 144	Lose 2003
0.1, 0.2, or 0.4 mg	Human	human	oral	3 weeks	Randomized trial in people · n = 127	van 2007
10-100 μg	Human	human	oral	single dose	Randomized trial in people · n = 116	Yamaguchi 2013
0.3 micrograms/kg	Human	human	Not reported	Not reported	Randomized trial in people · n = 100	Rocha 1988
0.3 micro g/kg	Human	human	Not reported	Not reported	Randomized trial in people · n = 100	Pleym 2004
0.3 microgram/kg	Human	human	Not reported	Not reported	Randomized trial in people · n = 95	Reynolds 1993
40 microg for 3 weeks then 20 microg for 3 weeks	Human	human	intranasal	6 weeks	Randomized trial in people · n = 93	Leebeek-Groenewegen 2001
0.03 microgram per kilogram	Human	human	intravenous	Not reported	Randomized trial in people · n = 92	Karnezis 1994
0.3 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 92	de 1992
20 micrograms	Human	human	Not reported	Not reported	Randomized trial in people · n = 91	Clagett 1995
30, 60, 120, 240, 360 or 480 microg	Human	human	oral lyophilisate	Not reported	Randomized trial in people · n = 84	Vande 2006
0.3 microgram/kg	Human	human	infusion	Not reported	Randomized trial in people · n = 79	Schött 1995
400 mug	Human	human	oral	12 weeks	Randomized trial in people · n = 73	Fai-Ngo 2005
0.3 micrograms/kg	Human	human	Not reported	Not reported	Randomized trial in people · n = 65	Gratz 1992
0.3 microgram/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 60	Seear 1989
0.3 micro g x kg(-1)	Human	human	intravenous	20 min	Randomized trial in people · n = 59	Wong 2003
Two doses of 0.3 micrograms/kg	Human	human	intravenous	Not reported	Randomized trial in people · n = 56	Rocha 1994
20 μg	Human	human	intravenous	single dose	Randomized trial in people · n = 54	Desborough 2023

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label reports prescription use. The regimen below is label information.

Reported routines and cautions

What people use it for

Initial oral desmopressin acetate tablet treatment for central diabetes insipidus in adults and children aged 4 years or olderS1

Reported regimens

Regimens that community sources report for Desmopressin. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Initial oral desmopressin acetate tablet treatment for central diabetes insipidus in adults and children aged 4 years or olderOfficial label dosing of an approved product	oralThis regimen covers oral desmopressin acetate tablets only.	0.05 mg per dose	twice daily	Not stated	Single official US label source.	S1

Cautions

The label warns about water intoxication and potentially fatal hyponatremia. Fluid restriction, medical supervision, and monitoring apply.S1
The label contraindicates treatment in patients with current or previous hyponatremia, creatinine clearance below 50 mL/min, or hypersensitivity to the drug or tablet components.S1

Status notes

The EMA list dated 6 September 2018 records nationally authorised products. It does not establish central authorisation or current availability in each country.S2

Community sources

S1DDAVP US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This review covers one selected official tablet regimen. It does not establish a separate non-vendor community regimen. The full label includes other patient groups, cautions, and administration conditions. No fixed treatment duration is stated for this selected starting regimen.

Questions and more

Ask a question about desmopressin

The answer links to every study it uses.

What does the evidence say about desmopressin?Is desmopressin tested in people?Compare with Oxytocin Compare with Melanotan I (afamelanotide)

Sources

Database: PepBank data for desmopressin (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about desmopressin

Desmopressin

ApprovedBanned in sport

Also known as DDAVP

What it is

Synthetic analog, 9 amino acids

Approval

Approved in the US and EU (Ddavp)

In sport

Banned in sport (WADA S5)

Studies

138 studies with results. 135 of them gave desmopressin, with 695 results.
622 in people72 in animals1 in lab cells

Best study in people

Randomized controlled trial with 385 people (2013)

Clinical trials

102 registered: 14 active or planned, 18 with posted results

Community use

Initial oral desmopressin acetate tablet treatment for central diabetes insipidus in adults and children aged 4 years or older

Dose as reported

Class

Species

Route

Duration

Design

Source

25 μg once daily

Human

human

oral

3 months

Randomized trial in people · n = 261

Sand 2013

0.3 μg/kg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 162

Manno 2011

50 μg

Human

human

oral

3 months

Randomized trial in people

Weiss 2013

75 μg

Human

human

oral

3 months

Randomized trial in people

Weiss 2013

300 micro g

Human

human

nasal spray

2 months

Randomized trial in people

Kadir 2002

25 μg

Human

human

oral

28 days

Randomized trial in people

Yamaguchi 2013

50 μg

Human

human

oral

28 days

Randomized trial in people

Yamaguchi 2013

100 μg

Human

human

oral

28 days

Randomized trial in people

Yamaguchi 2013

0.2 mg

Human

human

oral

2 weeks

Randomized trial in people

Hashim 2009

50 μg

Human

human

oral

12 weeks

Randomized trial in people

Yamaguchi 2020

25 μg

Human

human

oral

12 weeks

Randomized trial in people

Yamaguchi 2020

120 mcg/day, then 60 mcg/day for 15 days and 60 mcg every second evening for 15 days

Human

human

sublingual

3 months before withdrawal

Randomized trial in people

Ferrara 2014

25 µg once daily

Human

human

oral

3 months

Randomized trial in people

Rovner 2018

10, 25, 50, or 100 µg

Human

human

oral

4 weeks

Randomized trial in people · n = 757

Weiss 2012

50 and 75 μg

Human

human

oral

3 months

Randomized trial in people · n = 385

Weiss 2013

0.2-0.4 mg daily

Human

human

oral

6 months

Randomized trial in people · n = 251

Evans 2011

120/240 microg MELT; 0.2/0.4 mg tablets

Human

human

sublingual MELT; oral tablet

3 weeks per formulation

Randomized trial in people · n = 221

Lottmann 2007

melt 120/240 μg or tablet 0.2/0.4 mg

Human

human

oral

3 weeks per period

Randomized trial in people · n = 221

Juul 2013

120 µg

Human

human

oral melt

2 weeks

Randomized trial in people · n = 206

Montaldo 2012

0.2-0.6 mg

Human

human

oral

2 weeks

Randomized trial in people · n = 193

Schulman 2001

0.1, 0.2 or 0.4 mg

Human

human

oral

3 weeks

Randomized trial in people · n = 151

Mattiasson 2002

0.3 microgram per kilogram

Human

human

intravenous

Not reported

Randomized trial in people · n = 150

Hackmann 1989

0.1 mg, 0.2 mg, or 0.4 mg

Human

human

oral

3 weeks

Randomized trial in people · n = 144

Lose 2003

0.1, 0.2, or 0.4 mg

Human

human

oral

3 weeks

Randomized trial in people · n = 127

van 2007

10-100 μg

Human

human

oral

single dose

Randomized trial in people · n = 116

Yamaguchi 2013

0.3 micrograms/kg

Human

human

Not reported

Randomized trial in people · n = 100

Rocha 1988

0.3 micro g/kg

Human

human

Not reported

Randomized trial in people · n = 100

Pleym 2004

0.3 microgram/kg

Human

human

Not reported

Randomized trial in people · n = 95

Reynolds 1993

40 microg for 3 weeks then 20 microg for 3 weeks

Human

human

intranasal

6 weeks

Randomized trial in people · n = 93

Leebeek-Groenewegen 2001

0.03 microgram per kilogram

Human

human

intravenous

Not reported

Randomized trial in people · n = 92

Karnezis 1994

0.3 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 92

de 1992

20 micrograms

Human

human

Not reported

Randomized trial in people · n = 91

Clagett 1995

30, 60, 120, 240, 360 or 480 microg

Human

human

oral lyophilisate

Not reported

Randomized trial in people · n = 84

Vande 2006

0.3 microgram/kg

Human

human

infusion

Not reported

Randomized trial in people · n = 79

Schött 1995

400 mug

Human

human

oral

12 weeks

Randomized trial in people · n = 73

Fai-Ngo 2005

0.3 micrograms/kg

Human

human

Not reported

Randomized trial in people · n = 65

Gratz 1992

0.3 microgram/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 60

Seear 1989

0.3 micro g x kg(-1)

Human

human

intravenous

20 min

Randomized trial in people · n = 59

Wong 2003

Two doses of 0.3 micrograms/kg

Human

human

intravenous

Not reported

Randomized trial in people · n = 56

Rocha 1994

20 μg

Human

human

intravenous

single dose

Randomized trial in people · n = 54

Desborough 2023

Context

Route

Amount

How often

How long

Agreement

Sources

Initial oral desmopressin acetate tablet treatment for central diabetes insipidus in adults and children aged 4 years or olderOfficial label dosing of an approved product

oralThis regimen covers oral desmopressin acetate tablets only.

0.05 mg per dose

twice daily

Not stated

Single official US label source.

Desmopressin

Desmopressin at a glance

What is desmopressin?

The history of desmopressin

Desmopressin structure and chemistry

What desmopressin studies show

Blood and clotting

Kidneys and bladder

Hormones

Heart and blood vessels

Sleep

Pain

Key desmopressin studies

Desmopressin clinical trials

Is desmopressin approved?

Desmopressin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about desmopressin

Related peptides

Sources

Desmopressin

Desmopressin at a glance

What is desmopressin?

The history of desmopressin

Desmopressin structure and chemistry

What desmopressin studies show

Blood and clotting

Kidneys and bladder

Hormones

Heart and blood vessels

Sleep

Pain

Key desmopressin studies

Desmopressin clinical trials

Is desmopressin approved?

Desmopressin side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about desmopressin

Related peptides

Sources